Auckland UniServices Revenue and Competitors
Estimated Revenue & Valuation
- Auckland UniServices's estimated annual revenue is currently $26.9M per year.
- Auckland UniServices's estimated revenue per employee is $112,200
Employee Data
- Auckland UniServices has 240 Employees.
- Auckland UniServices grew their employee count by -18% last year.
Auckland UniServices's People
| Name | Title | Email/Phone |
|---|
Auckland UniServices Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.5M | 365 | 5% | N/A | N/A |
#2 | $21.1M | 188 | 5% | N/A | N/A |
#3 | $0.1M | 1 | -50% | N/A | N/A |
#4 | $12.4M | 122 | 3% | N/A | N/A |
#5 | $0.2M | 4 | N/A | N/A | N/A |
#6 | $38.4M | 301 | 17% | N/A | N/A |
#7 | $10M | 91 | 6% | N/A | N/A |
#8 | $5.7M | 62 | -6% | N/A | N/A |
#9 | $114.8M | 804 | 0% | N/A | N/A |
#10 | $5.3M | 58 | 7% | N/A | N/A |
What Is Auckland UniServices?
Auckland UniServices Limited is the commercial research, knowledge transfer and custom education company of the University of Auckland - dedicated to connecting the University’s capabilities to business and investors, Government and the community.
keywords:N/A
N/A
Total Funding
240
Number of Employees
$26.9M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Auckland UniServices News
2022-04-06 - Pandemic propels global effort to study rare vaccine side effects
Bruce Carleton, a clinical pharmacologist at the University of British ... from Petousis-Harris's university and Auckland UniServices Ltd.,...
2022-04-06 - Global Dysthymia Clinical Trial Market 2022 Growth Analysis ...
Auckland UniServices; Columbia Northwest Pharmaceuticals; New York State Psychiatric Institute; University Of Washington; Centre For Addiction...
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38.3M | 240 | -25% | N/A |
#2 | $63.1M | 240 | N/A | N/A |
#3 | $33.6M | 240 | 25% | N/A |
#4 | $87.5M | 241 | 7% | N/A |
#5 | $107.6M | 243 | 22% | N/A |